FIELD: medicine, biotechnology, pharmacology. SUBSTANCE: invention relates to peptide antagonists of zonuline. Invention involves peptide antagonists of zonuline as they determined in the invention claim that bind with receptors of zone of narrow contacts (zonula occludens) but don't modulate opening narrow contacts of mammalian cells. The advantage of invention involves the competitive inhibitory effect of indicated antagonists on binding toxin Zonula Occludens with its receptor resulting to inhibition of toxin ability and zonuline to modulate opening narrow contacts in mammals physiologically. EFFECT: valuable properties of antagonist. 8 dwg, 4 ex
